IL17A and breast carcinoma: Of note, repolarizing CX3CR1+ TAMs toward an immunostimulatory configuration with a monoclonal antibody targeting colony stimulating factor 1 receptor (CSF1R) ameliorated the activity of P+T against M/D-driven mammary carcinoma, to a magnitude similar to IL17A neutralization.